Drug Profile


Alternative Names: Alvameline maleate; Alvameline tartrate; LU 25109; LU 25109M; LU 25109T

Latest Information Update: 30 Jan 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Developer Forest Laboratories; Lundbeck A/S
  • Class Nootropics
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Urinary incontinence

Most Recent Events

  • 30 Jan 2001 Discontinued-II for Urinary incontinence in USA (Unknown route)
  • 27 Dec 2000 Phase-II clinical trials for Urinary incontinence in USA (Unknown route)
  • 24 Nov 2000 LU 25109 is now called alvameline (INN)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top